Canada markets close in 2 hours 2 minutes

Braxia Scientific Corp. (BRAX.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.00500.0000 (0.00%)
As of 09:30AM EDT. Market open.
Full screen
Previous Close0.0050
Open0.0000
Bid0.0050 x N/A
Ask0.0100 x N/A
Day's Range0.0050 - 0.0050
52 Week Range0.0050 - 0.0300
Volume0
Avg. Volume144,717
Market Cap1.416M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-0.0500
Earnings DateFeb 29, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Braxia Scientific Reports Q3 2024 Financial Results

    Toronto, Ontario--(Newsfile Corp. - February 29, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and nine months ended December 31, 2023. Complete financial statements along with rela

  • Newsfile

    Braxia Scientific Reports Mandatory Conversion of Debentures

    Toronto, Ontario--(Newsfile Corp. - January 15, 2024) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960), ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the mandatory conversion of $2,935,714 in convertible debentures, which matured on December 31, 2023, into 19,571,411 common shares at a conversion price of $0.15 per common share.About

  • Newsfile

    Braxia Scientific Reports Q2 2024 Financial Results and Provides Corporate Update

    Toronto, Ontario--(Newsfile Corp. - November 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and six months ended September 30, 2023. Complete financial statements along with relat